Literature DB >> 11399918

Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia.

G Coen1, S Calabria, G Bellinghieri, F Pecchini, F Conte, M G Chiappini, M Ferrannini, C Lagona, A Mallamace, M Manni, M DiLuca, D Sardella, F Taggi.   

Abstract

To evaluate the long-term results of parathyroidectomy (PTX) on parathyroid function, blood pressure and anemia, data of 45 patients with secondary Hyperparathyroidism in dialysis who had undergone PTX were collected retrospectively from 8 different dialysis units. The patients, 25 M and 20 F, mean age 56 +/- 11 years, who were followed up for an average period of 3.3 +/- 2.3 years, were divided into four groups according to the surgical procedure: 19 patients had had a subtotal PTX; 10 patients had undergone total PTX with autotransplantation (AT); 10 patients had had total PTX without AT, and 6 patients had undergone partial PTX. Taking a reduction in intact PTH > 50% as sign of successful PTX, only 5 patients did not attain this result. Considering values of PTH between 20 and 200 pg/ml at the mid-term observation (1-2 years) as the optimal result, values under 20 pg/ml as an expression of permanent hypoparathyroidism, and those above 200 pg/ml as indicating persistent/recurrent hyperparathyroidism, 65.5% of patients operated with subtotal PTX and total PTX + AT had a therapeutic success, versus 31.2% of patients in the other two groups, due to excess permanent hypoparathyroidism and persistent/recurrent hyperparathyroidism; 20 of 45 patients with preoperative hypertension experienced a statistically and clinically significant decrease in blood pressure levels. An increase in serum hemoglobin was also observed, despite a reduction of administered erythropoietin. In conclusion, the results of PTX obtained from this multicenter study are comparable to those reported by single leading centers. Recommended surgical procedures are subtotal PTX and total PTX with AT. The fall in blood pressure in hypertensive patients is clinically significant, and improvement in anemia is also observed with a reduction in erythropoietin dosage. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11399918     DOI: 10.1159/000045976

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  15 in total

1.  The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.

Authors:  T I Chang; S Abdalla; G M London; G A Block; R Correa-Rotter; T B Drüeke; J Floege; C A Herzog; K W Mahaffey; S M Moe; P S Parfrey; D C Wheeler; B Dehmel; W G Goodman; G M Chertow
Journal:  J Hum Hypertens       Date:  2015-06-04       Impact factor: 3.012

Review 2.  The Endocrine Role of Bone in Cardiometabolic Health.

Authors:  Rosemary DeLuccia; May Cheung; Rohit Ramadoss; Abeer Aljahdali; Deeptha Sukumar
Journal:  Curr Nutr Rep       Date:  2019-09

3.  Parathyroidectomy for the attainment of NKF-K/DOQI™ and KDIGO recommended values for bone and mineral metabolism in dialysis patients with uncontrollable secondary hyperparathyroidism.

Authors:  Bojan Kovacevic; Mile Ignjatovic; Vladan Zivaljevic; Vladimir Cuk; Milena Scepanovic; Zaklina Petrovic; Ivan Paunovic
Journal:  Langenbecks Arch Surg       Date:  2012-01-13       Impact factor: 3.445

4.  Secondary hyperparathyroidism and anemia in children treated by hemodialysis.

Authors:  Lorie B Smith; Jeffrey J Fadrowski; Chanelle J Howe; Barbara A Fivush; Alicia M Neu; Susan L Furth
Journal:  Am J Kidney Dis       Date:  2010-02       Impact factor: 8.860

5.  A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet.

Authors:  Yoshiyuki Oshiro; Hisataka Tanaka; Niro Okimoto
Journal:  Clin Exp Nephrol       Date:  2011-04-01       Impact factor: 2.801

6.  Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism.

Authors:  Elif Hindié; Paolo Zanotti-Fregonara; Pierre-Alexandre Just; Emile Sarfati; Didier Mellière; Marie-Elisabeth Toubert; Jean-Luc Moretti; Christian Jeanguillaume; Isabelle Keller; Pablo Ureña-Torres
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-28       Impact factor: 9.236

7.  Dynamics of parathyroid hormone secretion after total parathyroidectomy and autotransplantation.

Authors:  Luiz Carlos Conti-Freitas; Maria Cristina Foss-Freitas; Leandro Junior Lucca; Jose Abrão Cardeal da Costa; Rui Celso Martins Mamede; Milton Cesar Foss
Journal:  World J Surg       Date:  2009-07       Impact factor: 3.352

8.  Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism.

Authors:  Chen Chen; Hua Wu; Lin Zhong; Xin Wang; Zhuang-Jie Xing; Bi-Hu Gao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

9.  Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function.

Authors:  Miguel Echenique-Elizondo; José Antonio Amondarain; Fernando Vidaur; Carmen Olalla; Fernando Aribe; Adolfo Garrido; José Molina; Maria Teresa Rodrigo
Journal:  World J Surg       Date:  2007-05-22       Impact factor: 3.352

10.  Parathyroidectomy and heart rate variability in patients with stage 5 CKD.

Authors:  Jing Zhang; Xiangbao Yu; Bin Sun; Jianling Bai; Yongyue Wei; Xiaoming Zha; Yiyao Cui; Ming Zeng; Jingjing Zhang; Jia Liu; Huijuan Mao; Bo Zhang; Haibin Ren; Yifei Ge; Xueqiang Xu; Zhixiang Shen; Changying Xing; Kejiang Cao; Ningning Wang
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.